Encompass Health (EHC) Intrinsic Value Calculator

Updated: Nov 20, 2026

Encompass Health (EHC) trades at $133.65 against a base-case intrinsic value of $102.95 — roughly a 30% premium to fair value. The model starts from $6.89 in expected earnings per share, grows it at 9.7% annually (analyst consensus) decaying to a 4% terminal rate by Year 5, applies a 17.3x exit multiple, and discounts the result back at 10% per year. At today's price, the market is pricing in either faster earnings growth or a higher exit multiple than EHC's own history supports. Use the sliders below to see what growth assumptions would be needed to justify the current price.

Overvalued by 23.0%
Current Price
$133.65
Intrinsic Value
$102.95
Implied Upside: -23.0%

Discounted Cash Flow with Growth Decay Model

Customize Your Valuation

Adjust the assumptions below to model different scenarios. The intrinsic value updates in real-time.

Conservative
Base Case
Aggressive
Time Horizon 5 years
3 years 10 years
Initial Growth Rate 9.7%
0% (No Growth) 50% (High Growth)
Terminal Growth Rate 4.0%
0% (Decline) 6% (GDP+)
Discount Rate (Required Return) 10.0%
5% (Low Risk) 15% (High Risk)
Exit PE Multiple 17.3x
8x (Value) 40x (Growth)
Calculated Intrinsic Value
$102.95
--
Tradestie Long-Horizon Cycle Intelligence (2016–2025 • Split-Invariant)

Tradestie Long-Horizon Financial Resilience & Peer Growth Benchmark (10-Year Cycle Analysis)

Outside-View Peer Growth Benchmark Services-Hospitals • 2498+ US Equities Benchmarked

Across 19 years of multi-cycle financial history in Services-Hospitals, only 18.0% of peer companies at >$5B revenue scale (50 historical 5-year windows; industry median CAGR: 5.0%/yr) sustained ≥8%/yr 5-year compound revenue growth (broad >$5B equity base rate: 25.6%).

≥5%/yr (5Y)
50.0%
All >$5B: 42.8%
≥10%/yr (5Y)
12.0%
All >$5B: 17.5%
≥15%/yr (5Y)
0.0%
All >$5B: 8.0%
≥20%/yr (5Y)
0.0%
All >$5B: 4.1%
≥25%/yr (5Y)
0.0%
All >$5B: 2.5%
≥30%/yr (5Y)
0.0%
All >$5B: 1.4%
10-Yr Revenue Scale
$3.64B → $5.94B
9Y CAGR: +5.6%/yr • 5Y: +10.7%
2008–2009 Cycle Trough Floor
Post-2009 Series
Tracked from FY2016
2022 Rate-Shock Floor
12.4% Op Margin
FY2022 Rev: $4.35B (+8.3% YoY)
Latest vs Cycle Median Margin
N/A vs 13.9% med
100% Operating Profitable Across Tracked Cycles
Multi-Cycle Revenue & Operating Margin Trajectory (2016–2025) Expansion 2008–09 / 2022 Macro Stress
16%
'16
15%
'17
13%
'18
13%
'19
16%
'20
14%
'21
12%
'22
'23
'24
'25
Inspect All 10 Fiscal Years of Annual Revenue & Operating Margin History Toggle Annual Ledger ↓
Fiscal Year Annual Revenue YoY Growth Operating Income Operating Margin Macro Cycle Regime
FY2025 (2025-12) $5.94B +10.5% N/A — Standard
FY2024 (2024-12) $5.37B +11.9% N/A — Standard
FY2023 (2023-12) $4.80B +10.4% N/A — Standard
FY2022 (2022-12) $4.35B +8.3% $540M 12.4% 2022 Rate Shock
FY2021 (2021-12) $4.01B +12.6% $560M 13.9% Standard
FY2020 (2020-12) $3.57B -22.6% $564M 15.8% Standard
FY2019 (2019-12) $4.61B +7.7% $612M 13.3% Standard
FY2018 (2018-12) $4.28B +9.3% $555M 13.0% Standard
FY2017 (2017-12) $3.91B +7.4% $578M 14.8% Standard
FY2016 (2016-12) $3.64B — $588M 16.1% Standard

Year-by-Year Projections

EPS growth decays from initial rate to terminal rate over the projection period.

Year Growth Rate EPS Stock Price Present Value

Price Projection

Sensitivity Analysis

How intrinsic value changes with different growth and discount rate assumptions.

Model Inputs
Base EPS $6.89
Current Price $133.65
Historical PE 17.3x
Analyst Growth Est. 9.7%
How It Works

Growth Decay Model: We project EPS growth that gradually slows from the initial rate to a terminal rate (typically 3-4%, matching long-term GDP growth).

Terminal Value: At the end of the projection period, we apply an exit PE multiple to estimate the future stock price.

Discounting: Future values are discounted back to today using your required rate of return (discount rate).